

EGIDE

Euronext C - FR0000072373 - GID

✓ Signing of the sale/lease back of the Cambridge building for \$6 million

A little over a week ago, Egide announced that Banc of California had agreed to postpone the deadline to September 30 to find a financial partner in the USA. The group has just announced that the project to refinance the Cambridge building for \$6 million has been concluded with Tempus Cambridge LLC. "The lease attached to the transaction is for 15 years with an annual rent of \$0.4 million".

This agreement will make it possible to repay long-term US loans amounting to \$2.5 million but will also help to obtain revolving credit lines which finance the WCR of US entities.

This cash injection will give the group the means to continue investing in its industrial facilities in the United States, which will help improve its competitiveness. Moreover, from a purely accounting point of view, this will most likely allow its American auditors to remove "their doubts".

Egide is finding some breathing space in an environment which, due to current events, is leading to a marked increase in investments in the military field. The group must therefore seize this opportunity, aided by a modernized industrial tool, to increase its customer portfolio, which was one of its weaknesses.

Opinion & price target.

This publication is positive and reinforces our opinion.

We will wait to discuss with the financial department to assess the impacts on our forecasts but in any case, Egide is thus equipping itself with means offering it significant visibility.

In the meantime, we maintain we confirm our price target and our Buy opinion.

BUY

Sale/lease back agreement

BPI Label - Innovative company- PEA-PME Eligible

TARGET BEFORE € 1.78 € 1.78

SHARE PRICE (6.28.22) POTENTIAL € 0.94 + 88%

CAPITALISATION FLOTTANT € 9.73m € 8.56m

Ratios		2022 e	2023 e	2024e	
EV/Sales		0,5	0,4	0,4	
EV/EBIT		22,2	12,2	7,8	
P/E		24,6	9,7	6,7	
P/CF		9,0	4,9	2,7	
Dividend Yield		0,0	0,0	0,0	
Data per share	2021	2022e	2023e	2024e	
EPS	0,02	0,04	0,10	0,14	
%Change	nr	0,97	1,53	0,46	
FCF	-0,03	0,00	0,08	0,26	
%Change	nr	nr	nr	2,26	
Dividend	-	-	-	-	
Income Statement (€m)	2021	2022e	2023e	2024e	
Net Sales	32,5	36,3	38,5	40,9	
%Change	8,4%	11,6%	6,2%	6,2%	
EBIT	0,8	0,8	1,4	1,9	
% Sales	2,5%	2,2%	3,7%	4,6%	
Net Result	0,2	0,4	1,0	1,5	
% Sales	0,6%	1,1%	2,6%	3,6%	
Cash Flow Statement (€m)	2021	2022e	2023e	2024e	
FCF	-0,4	0,0	0,8	2,7	
Net Debt	8,3	8,3	7,5	4,9	
Shareholder Equity	11,4	11,8	12,8	14,3	
Gearing	73,0%	70,6%	58,7%	34,2%	
ROCE	2,6%	2,6%	4,4%	6,2%	
Shareholders					
Vatel Capital	5,0%				
Sigma Gestion	5,0%				
Management	2,0%				
Free Float	88,0%				
Performances	2022	3m	6m	1 Year	
Egide	-34,3%	-34,3%	-33,8%	-36,7%	
CAC Small	-24,3%	-13,7%	-23,8%	-27,1%	
12 months Low-High	0,78	1,75			
Liquidity	2022	3m	6m	1 Year	
Cumulative volume (000)	10 035	3 493	10 477	14 963	
% of capital	97,0%	33,8%	101,3%	144,6%	
% of Free Float	110,2%	38,4%	115,1%	164,3%	
€ Million	13,1	3,8	13,8	19,8	

H1 Sales :July, 21

Next Event




Snapshot Egide

Egide articulates its activity through two technologies that are glass-metal and ceramic cases which makes it one of the few actors in the world to control them. These housings make it possible to ensure perfect hermeticity in environments that may be subject to high thermal and / or atmospheric stresses. Egide provides highly resistant interconnection boxes in sensitive environments (Space, Defense, Security, Aeronautics, Telecommunications, Energy, ...), solutions that guarantee the optimal reliability of electronic systems or complex chips. In February 2017, the group acquired Santier, a US company specializing in the manufacture of dissipative components and materials.

Fondamental Matrix

Investment Profile





Target Price & rating history

Date	Туре	Opinion	Price per share	Price Target
6/17/22	Amendment	Buy	€ 0.87	€ 1.78
3/30/22	2021 Annual results	Buy	€ 1.44	€ 1.78
1/26/22	2021 Annual Sales	Buy	€ 1.595	€ 1.78
12/13/21	Press Release	Buy	€ 1.26	€ 1.85
9/29/21	H1 Results	Buy	€ 1.415	€ 1.76
7/24/21	H1 Sales	Buy	€ 1.56	€ 1.74
6/25/21	General Assembly	Buy	€ 1.475	€ 1.74



Financial Data

Income Statement (€ m)	2019	2020	2021	2022e	2023e	2024e
Revenues	31,8	30,6	32,5	36,3	38,5	40,9
Purchase	13,1	12,5	12,7	14,5	15,4	16,4
Externals costs	4,8	2,3	6,5	5,3	5,6	5,9
Personnals Costs	13,7	13,6	14,0	13,7	14,2	14,7
Amortization	1,4	1,6	1,5	1,7	1,6	1,6
other	-0,3	2,3	3,4	0,0	0,0	0,0
EBIT	-2,2	2,0	0,8	0,8	1,4	1,9
Financial Result	-0,6	-0,6	-0,4	-0,4	-0,4	-0,4
Tax	0,0	-0,4	-0,2	0,0	0,0	0,0
Net Result	-2,8	1,0	0,2	0,4	1,0	1,5
Balance Sheet (€ m)	2019	2020	2021	2022e	2023e	2024e
Fixed Assets	11,6	10,0	12,6	11,5	11,2	10,6
Stock Inventories	7,5	8,1	7,6	9,1	9,6	9,1
Accounts Recevaible	6,5	5,0	4,9	7,0	7,5	8,0
Other Currents Assests	0,2	3,2	1,4	0,5	0,5	0,6
Cash & Equivalents	1,5	1,4	1,6	1,5	2,2	4,6
TOTAL Assets	27,2	27,8	28,1	29,6	31,1	32,9
Shareholders' Equity	10,4	10,6	11,4	11,8	12,8	14,3
Provisions	0,8	0,8	0,9	0,9	1,0	1,0
Financial Debt	6,9	6,6	7,7	7,6	7,5	7,3
Accounts Payables	5,9	7,2	5,3	7,0	7,5	8,0
TOTAL Liabilitites	27,2	27,8	28,1	29,6	31,1	32,9
		,			•	•
Cash Flow Statements (€ m)	2019	2020	2021	2022e	2023e	2024e
Cash Flow from Operating Activities	-1,1	2,5	-1,2	2,1	2,6	3,0
Change in Net Working Capital	0,2	-0,8	0,7	1,0	0,6	-0,5
Cash Flow from Operations	-1,3	1,7	-0,5	1,1	2,0	3,6
Cash Flow from Investing	-0,9	-0,8	0,1	-1,1	-1,2	-0,9
Capital Increase	2,4	0,0	0,0	0,0	0,0	0,0
Funding Flow	0,2	0,3	0,7	-0,1	-0,1	-0,2
Cash Flow from Financing	1,3	-0,8	0,5	-0,1	-0,1	-0,2
Net Change in cash position	-0,9	-0,1	0,2	-0,1	0,7	2,5
RATIOS	2019	2020	2021	2022e	2023e	2024e
Ebitda Margin	-0,7%	3,9%	-3,2%	6,9%	7,7%	0,0%
EBIT Margin	-6,9%	6,4%	2,5%	2,2%	3,7%	4,6%
Net Margin	-8,9%	3,2%	0,6%	1,1%	2,6%	3,6%
ROE	-27,1%	9,3%	1,8%	3,3%	7,8%	10,2%
ROCE	-27,1% -7,3%	9,5% 6,9%	2,6%	2,6%	4,4%	6,2%
Gearing	-7,3 <i>%</i> 82,5%	72,9%	73,0%	70,6%	58,7%	34,2%
	02,370	, 2,3/0	. 3,070	. 0,070	30,170	3 -1,2/0
FCF per share	-0,21	0,08	-0,03	0,00	0,08	0,26
EPS (€)	-0,27	0,10	0,02	0,04	0,1	0,1
Dividend per share (€)	0,0	0,0	0,0	0,0	0,0	0,0
Dividen Yield	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%

Estimates : GreenSome Finance 2019-2020-2021 with new shares



Rating Definition

BUY	NEUTRAL	SELL
Upside > +10%	-10% < Upside < +10%	Upside < -10%

Disclosures

Corporate Finance operation in progress or completed during the last 12 months	GreenSome Consulting and affiliate owns common equity securities of this subject company	Financial Analysis Contract	Notice to the company before publication	Liquidity Contract	Liquidity Provider
NO	NO	YES	YES	NO	NO

This publication was prepared by Greensome Finance on behalf of GreenSome Consulting. It is issued for informational purposes only and does not constitute a solicitation of orders to buy or sell securities mentioned therein.

The information contained in this publication and all opinions contained therein are based on sources believed reliable. However Greensome Consulting does not warrant the accuracy or completeness of this information and no one can rely. All opinions, projections and / or estimates contained in this publication reflect the decision of Greensome Consulting on the date and may be subject to change without notice. This publication is for informational purposes only to professional investors who are supposed to develop their own investment decisions without relying improperly on this publication. Investors must make their own judgments about the appropriateness of investing in any securities mentioned in this publication taking into account the merits and risks attached to them, their own investment strategy and their legal status, fiscal and financial. Past performance is by no means a guarantee for the future. Because of this publication, neither Greensome Consulting nor any of its officers or employees, cannot be held responsible for any investment decision. In accordance with the regulations and to prevent and avoid conflicts of interest with respect to any investment recommendations, Greensome Consulting has developed and maintains an effective operational management of conflicts of interest. The system for managing conflicts of interest is to prevent, with reasonable certainty, any breach of the principles and rules of professional conduct. It is constantly updated to reflect regulatory changes and changes in the activity of Greensome Consulting. Greensome Consulting intends at all times, act with respect for the integrity of the market and the primacy of the interests of its customers. To this end, Greensome Consulting has set up an organization's business and the procedures commonly called "Chinese Wall" whose purpose is to prevent the improper circulation of confidential information, and organizational and administrative arrangements to ensure transparency in situations likely to be perceived as conflicts of interest by investors. This publication is in terms of its distribution in the UK, only for people considered persons licensed or exempt under the Financial Services Act 1986 in the United Kingdom or any regulations passed under it or to persons as described in section 11 (3) of the Financial Services Act 1986 (Investment Advertisement) (Exemptions) Order 1997 and is not intended to be distributed or communicated, directly or indirectly, to any other type of person. The distribution of this publication in other jurisdictions may be restricted by applicable law, and anyone who would come to be in possession of this book should learn and observe such restrictions.